Komori
KYORIN Pharmaceutical (4569) · PolicyRestated

Sustained Enhancement of Corporate Value and Management Transparency

First written in FY2017. 3 of 4 entries say "Restated". Latest entry: FY2024.

4entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY20242017: 120172018: 120182019: 120192020: 020202021: 020212022: 020222023: 020232024: 12024
Same theme, other companies
Continuous Strengthening of Corporate Governance and Internal Control SystemsA theme 968 companies write about · 4 as a headwind · 1068 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 185 companies compared. The sentences above are computed from all 185.Comparing 200 of the theme's 1074 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024RestatedAnnual report

    「The company regards “continuous enhancement of corporate value” as its top management priority. Achieving this requires establishing a management environment that earns the trust of society, so we regard enhancing corporate governance as an important issue and are working to accelerate decision-making, strengthen oversight of the appropriateness of management, and ensure transparency in corporate activities rooted in corporate ethics.」

    The company continues to strengthen corporate governance, including decision-making, oversight and transparency, while continuously enhancing corporate value.
  2. FY2019RestatedAnnual report

    「The company regards “continuous enhancement of corporate value” as its top management priority. Achieving this requires establishing a management environment that earns the trust of society, so we regard enhancing corporate governance as an important issue」

    The company continues to treat continuous enhancement of corporate value and stronger corporate governance as important management issues.
  3. FY2018RestatedAnnual report

    「The company regards “continuous enhancement of corporate value” as its top management priority. Achieving this requires establishing a management environment that earns the trust of society, so we regard enhancing corporate governance as an important issue」

    The company continues to treat continuous enhancement of corporate value and stronger corporate governance as important management issues.
  4. FY2017First statedAnnual report

    「We regard the “continuous enhancement of corporate value” as management’s most important priority. To achieve this, it is necessary to establish a management environment that earns society’s trust. We therefore regard strengthening corporate governance as an important issue and are working to accelerate decision-making, strengthen oversight of the appropriateness of management and ensure transparency in corporate activities rooted in corporate ethics.」

    The Group identifies corporate value enhancement as its top priority and seeks to strengthen decision-making, oversight and transparency.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.